NO20081945L - Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse - Google Patents

Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse

Info

Publication number
NO20081945L
NO20081945L NO20081945A NO20081945A NO20081945L NO 20081945 L NO20081945 L NO 20081945L NO 20081945 A NO20081945 A NO 20081945A NO 20081945 A NO20081945 A NO 20081945A NO 20081945 L NO20081945 L NO 20081945L
Authority
NO
Norway
Prior art keywords
alkyl
fluorine atoms
compounds
receptor
activity
Prior art date
Application number
NO20081945A
Other languages
English (en)
Norwegian (no)
Inventor
David Gwyn Cooper
Graham Walker
Ian Thomson Forbes
Vincenzo Garzya
Brian Budzik
Jian Jin
Dongchuan Shi
Paul William Smith
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20081945L publication Critical patent/NO20081945L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20081945A 2005-09-30 2008-04-23 Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse NO20081945L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds
PCT/GB2006/003590 WO2007036715A2 (en) 2005-09-30 2006-09-27 Compounds which have activity at m1 receptor and their uses in medicine

Publications (1)

Publication Number Publication Date
NO20081945L true NO20081945L (no) 2008-06-04

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081945A NO20081945L (no) 2005-09-30 2008-04-23 Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse

Country Status (24)

Country Link
US (2) US8283364B2 (ru)
EP (1) EP1943230B1 (ru)
JP (1) JP5209480B2 (ru)
KR (2) KR20130091791A (ru)
CN (1) CN101321736B (ru)
AR (1) AR056103A1 (ru)
AT (1) ATE492537T1 (ru)
AU (1) AU2006296369B2 (ru)
BR (1) BRPI0616609A2 (ru)
CA (1) CA2624504C (ru)
CR (1) CR9904A (ru)
DE (1) DE602006019119D1 (ru)
EA (1) EA016286B1 (ru)
IL (1) IL190219A (ru)
JO (1) JO2634B1 (ru)
MA (1) MA29849B1 (ru)
MY (1) MY148504A (ru)
NO (1) NO20081945L (ru)
NZ (1) NZ566508A (ru)
PE (1) PE20070490A1 (ru)
TW (1) TWI389905B (ru)
UA (1) UA101299C2 (ru)
WO (1) WO2007036715A2 (ru)
ZA (1) ZA200802167B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
EP1937670A1 (en) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
DE602006019119D1 (de) 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
JP2017533227A (ja) * 2014-11-03 2017-11-09 ウィリアム・ボーモント・ホスピタルＷｉｌｌｉａｍ Ｂｅａｕｍｏｎｔ Ｈｏｓｐｉｔａｌ 低活動膀胱症候群を治療するための方法
JP6811187B2 (ja) * 2015-04-29 2021-01-13 ヤンセン ファーマシューティカ エヌ．ベー． インドロン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
EP4144736A1 (en) 2015-04-29 2023-03-08 JANSSEN Pharmaceutica NV Azabenzimidazoles and their use as ampa receptor modulators
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANAGONISTS
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
DE60013464T2 (de) 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001057019A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
SI1975164T1 (sl) 2001-04-18 2010-05-31 Euro Celtique Sa Oktahidrobenzimidazolonske spojine kot analgetiki
EP1386920A4 (en) 2001-04-20 2005-09-14 Banyu Pharma Co Ltd DERIVATIVES OF BENZIMIDAZOLONE
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
CA2457647A1 (en) 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
WO2003082333A1 (fr) 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
US7279490B2 (en) 2002-06-17 2007-10-09 Merck & Co, Inc. Ophthalmic compositions for treating ocular hypertension
EP1569646A2 (en) 2002-12-13 2005-09-07 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
WO2005009996A1 (en) 2003-07-23 2005-02-03 Wyeth Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
JP2008518905A (ja) 2004-11-02 2008-06-05 ファイザー株式会社 スルホニルベンゾイミダゾール誘導体
US7300947B2 (en) 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
EP1937670A1 (en) 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
DE602006019119D1 (de) 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8239995B2 (en) 2006-09-08 2012-08-14 The Gillette Company Toothbrush with multiple bristles states
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20080255195A1 (en) 2008-10-16
MY148504A (en) 2013-04-30
EA016286B1 (ru) 2012-03-30
US8481566B2 (en) 2013-07-09
KR20080049090A (ko) 2008-06-03
AU2006296369B2 (en) 2012-12-20
KR20130091791A (ko) 2013-08-19
NZ566508A (en) 2011-07-29
WO2007036715A2 (en) 2007-04-05
UA101299C2 (ru) 2013-03-25
KR101374458B1 (ko) 2014-03-17
CN101321736A (zh) 2008-12-10
BRPI0616609A2 (pt) 2011-06-28
EP1943230B1 (en) 2010-12-22
CA2624504A1 (en) 2007-04-05
TW200806657A (en) 2008-02-01
AU2006296369A1 (en) 2007-04-05
EA200801001A1 (ru) 2008-08-29
IL190219A0 (en) 2008-11-03
US8283364B2 (en) 2012-10-09
EP1943230A2 (en) 2008-07-16
PE20070490A1 (es) 2007-05-30
CR9904A (es) 2008-07-29
CA2624504C (en) 2014-07-08
CN101321736B (zh) 2012-04-04
TWI389905B (zh) 2013-03-21
ZA200802167B (en) 2009-08-26
WO2007036715A3 (en) 2007-05-18
ATE492537T1 (de) 2011-01-15
AR056103A1 (es) 2007-09-19
US20080058378A1 (en) 2008-03-06
JP2009512635A (ja) 2009-03-26
DE602006019119D1 (de) 2011-02-03
MA29849B1 (fr) 2008-10-03
JO2634B1 (en) 2012-06-17
IL190219A (en) 2012-10-31
JP5209480B2 (ja) 2013-06-12

Similar Documents

Publication Publication Date Title
NO20081945L (no) Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse
NO20084048L (no) Benzimidazoler som har aktivitet ved M1 receptor og deres anvendelser i medisin
CY1121888T1 (el) (+)-2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλοσουλφονυλαιθυλ]-4-ακετυλαμινοϊσοϊνδολινο-1,3-διονη: μεθοδοι χρησης και συνθεσεις αυτης
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20062549L (no) Substituerte arylpyrazoler anti-paresittmidlert
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
CY1115361T1 (el) Στερεες μορφες περιλαμβανοντας (+)-2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλσουλφονυλαιθυλ]-4-ακετυλαμινοϊσοϊνδολιν-1,3-διονη, συνθεσεις εξ' αυτων, και χρησεις εξ' αυτων
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20050828L (no) lndol-3-svovelderivater
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20082096L (no) Azaindol-2-karboksamidderivativer
ATE494926T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
NO20044764L (no) 1-(aminoalkyl)-3-sulfonylindol og -indazolderivater som 5-hydroksytryptamin-6 ligander
UY32604A (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina)adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
BR112012032813A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença ou condição.
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application